Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

@article{Baden2020EfficacyAS,
  title={Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine},
  author={Lindsey Robert Baden and Hana M. El Sahly and Brandon J Essink and Karen L Kotloff and Sharon E. Frey and Richard M Novak and David Diemert and Stephen A. Spector and Nadine G. Rouphael and Clarence Buddy Creech and John Mcgettigan and Shishir Kehtan and Nathan Segall and Joel Solis and Adam Brosz and Carlos Fierro and Howard I. Schwartz and Kathleen M. Neuzil and Lawrence Corey and Peter Gilbert and Holly E Janes and Dean A. Follmann and Mary A. Marovich and John R. Mascola and Laura Polakowski and Julie E Ledgerwood and Barney S. Graham and Hamilton Bennett and Rolando Pajon and Conor Knightly and Brett Leav and Weiping Deng and Honghong Zhou and Shu Han and M. Ivarsson and Jacqueline M. Miller and Tal Z. Zaks},
  journal={The New England Journal of Medicine},
  year={2020}
}
Abstract Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. Methods This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers… 

Figures and Tables from this paper

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
TLDR
The mRNA-1273 vaccine continued to be efficacious in preventing Covid-19 illness and severe disease at more than 5 months, with an acceptable safety profile, and protection against asymptomatic infection was observed.
Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster
TLDR
A preliminary evaluation of a clinical study designed to target emerging SARS-CoV-2 variants as booster vaccines in participants previously vaccinated approximately 6 months earlier with two doses of the prototype vaccine, mRNA-1273, and modified COVID-19 mRNA vaccines, which appeared to be more effective at increasing neutralization of the B.1.351 variant.
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
TLDR
NVX-CoV2373 was well tolerated and demonstrated a high overall VE (>90%) for prevention of Covid-19, with most cases due to variant strains.
Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
TLDR
The NVX-CoV2373 vaccine was efficacious in preventing Covid-19, which was predominantly mild to moderate and due to the B.1.351 disease, and serious adverse events were rare in both groups.
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
TLDR
A two-dose regimen of NVX-CoV2373 conferred 89.7% protection against a blend of prototype and variant Covid-19, demonstrated high efficacy against the B.1.7 variant, and had a reassuring safety profile.
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
TLDR
The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against CO VID-19.
Review the safety of Covid-19 mRNA vaccines: a review
TLDR
The present review was designed to provide an update on the current state of science related to the safety and efficacy of SARS-CoV-2 mRNA vaccines.
Correction to: The safety of Covid-19 mRNA vaccines: a review
TLDR
The present review was designed to provide an update on the current state of science related to the safety and efficacy of SARS-CoV-2 mRNA vaccines.
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
TLDR
MRNA-1273 elicited robust serologic immune responses across age, sex, and SARS-CoV-2 status, consistent with its high COVID-19 efficacy, and higher immune responses in those previously infected support a booster-type effect.
...
...

References

SHOWING 1-10 OF 29 REFERENCES
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
TLDR
The phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein in healthy adults found it induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100- μg dose in a phase 3 vaccine trial.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
TLDR
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
TLDR
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
TLDR
Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung.
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
TLDR
At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum, and the addition of adjuvant resulted in enhanced immune responses, was antigen dose–sparing, and induced a T helper 1 (Th1) response.
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
TLDR
It is shown that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology.
A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
TLDR
The BNT162b2 vaccine candidate fully protected the lungs of immunised rhesus macaques from infectious SARS-CoV-2 challenge and generated strong TH1 type CD4+ and IFNγ+ CD8+ T-cell responses in mice and rhesu macaques.
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
TLDR
It is shown that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS- CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response.
Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)
TLDR
This review focuses on the ongoing SARS-CoV-2 vaccine development efforts with emphasis on the nonclinical safety assessment and discusses emerging preliminary data from nonclinical and clinical studies.
...
...